
The treatment of zzso with zzso agents such as zzso beta and zzso zzso early in the disease course, is increasingly recognized as benefiting patient zzso zzso is a chronic inflammatory disease of the central nervous system with zzso hallmarks of zzso zzso zzso loss and zzso While inflammation and zzso induce neurological deficit, which is at least partly zzso zzso loss beyond the threshold of compensation is always accompanied by irreversible clinical disease zzso These zzso findings suggest that, in addition to reducing the impact of zzso the ability to prevent zzso zzso is a vital component of zzso zzso Approved zzso therapies shift zzso status from a zzso response toward more beneficial zzso zzso Clinical studies also suggest that beta zzso helps to zzso and may at least partially reverse, zzso zzso Future work in this area will be aided by using magnetic resonance imaging zzso to follow zzso zzso and zzso of zzso zzso by MR zzso both of which are potential markers of structural zzso The urgent need to identify definitive markers of zzso in humans zzso Such markers explain more about the underlying mechanisms of early zzso zzso 

